Keywords
sickle cell disease
aphrodisiacs
corpus cavernosum puncture
How to Cite
Abstract
Introduction :
ischaemic priapism is an uncommon andrological emergency, the main etiologies being sickle cell disease and abuse of aphrodisiac substances. Treatment aims to achieve rapid detumescence by intra-cavernosal administration of an alpha-stimulant drug, sometimes combined with cavernospongiosal shunting. The aim of this study is to present our experience in the management of ischaemic priapism.
Material and method :
This was a retrospective descriptive study from January 2015 to June 2023, including all patients admitted to the emergency department of the National Hospital of Zinder (HNZ) for priapism who had received treatment. The number of episodes per patient was not considered in this study.
Results :
A total of 22 patients were enrolled with a median age of 23.86 years (7-53 years). The mean time to consultation was 23.31 hours (extremes 3 hours and 82 hours) and more than 63% were admitted before the 10th hour. The main etiologys were sickle cell disease (59.10%, n=13), aphrodisiacs (31.82%, n=7) and idiopathic disorders (9.10%, n=2). All patients had undergone cavernous body lavage with intra cavernous injection of Etilefrine. Detumescence was complete in 82% (n=18) of cases and incomplete in 18% (n=4).
Conclusion :
Sickle cell disease and erectogenic drugs are the main causes of priapism in our study. Puncture and cleaning with saline of the corpora cavernosa combined with intracavernosal injection of alpha-stimulant drugs gave good results within 72 hours.
References
1. Wein AJ, Kavoussi LR, Partin AW, Louis R, Andrew C. Novick, Craig A Peter et al. CampbellWalsh urology. 11th ed. Philadelphia: Elsevier; 2016.
2. Broderick GA, Kadioglu A, Bivalacqua TJ, Ghanem H, Nehra A, Shamloul R. Priapism: pathogenesis, epidemiology, and management. J Sex Med 2010;7(1pt2):476–500
3. Droupy S, Giuliano F. Priapismes. Prog En Urol. juill 2013;23(9):638-46.
4. Salonia A, Eardley I, Giuliano F, Hatzichristou D, Moncada I, Vardi Y, et al. European Association of Urology Guidelines on Priapism. Eur Urol. févr 2014;65(2):480-9.
5. Carnicelli D, Akakpo W. Le priapisme : diagnostic et prise en charge. Prog En Urol. nov 2018;28(14):772-6.
6. Kane R, Niang L, Berthe H, Ndiaye A, Diao B, Ndoye A, et al. Prise en charge du priapisme à Dakar. Basic Clin Androl. mars 2012;22(1):36-41.
7. 7. Whyte N, Morrison-Blidgen B, Asnani M. Priapism in Sickle Cell Disease: An Evaluation of the Knowledge of an at Risk Population in Jamaica. Sex Med. 1 juin 2021;9(3):100339-100339.
8. Upadhyay J, Dhabuwala CB, Perlmutter AD, Connor JP. Priapism associated with sickle cell hemoglobinopathy in children: long-term effects on potency. The Journal of Urology. 1996;155(4):1412-1414.
9. Dekou A, Ouegnin GA, Konan PG, Kouame B, Manzan K. Les étiologies et facteurs de risque du priapisme à partir d’une série colligée dans le service d’urologie du CHU de Cocody. Rev Int Sc Méd 2006;8(3):27–30.
10. Habou O, Adamou H, Amadou Magagi I, Amadou S, Magagi A, Malam Bade A, et al. Prise en charge du priapisme ischémique aigu à l’Hôpital National de Lamordé de Niamey. Afr J Urol. déc 2017;23(4):338-41.
11. Gondran-Tellier B, André M, Baboudjian M, Lechevallier E, Boissier R. Le priapisme artériel. Prog En Urol - FMC. sept 2020;30(3):F77-80.
12. Bullock N, Steggall M, Brown G. Emergency Management of Priapism in the United Kingdom: A Survey of Current Practice. J Sex Med. 1 avr 2018;15(4):476-9.
13. Boissier R, Gondran-Tellier B, Lechevallier E. Le priapisme ischémique. Prog En Urol - FMC. déc 2020;30(4):F117-20.
14. Eland IA, van der Lei J, Stricker BHC, Sturkenboom MJCM. Incidence of priapism in the general population. Urology. mai 2001;57(5):970-2.
15. Bouya PA, Odzébé AWS, Koumou Moritoua RD, Elira Dokékias A. Priapisme aigu drépanocytaire: analyse de 20 cas traités au CHU de Brazzaville. Basic Clin Androl. mars 2011;21(1):34-7.
16. Gbadoe AD, Akakpo-Vidah A, Pitche P, Assimadi JK. Priapisme drépanocytaire : prise en charge par injections intracaverneuses d’étiléfrine. Médecine Tropicale. 2000;60(1):53-56.
17. Kassogué A, Coulibaly M, Ouattara Z, Diarra A, Tembely A, El MJ, et al. Aspects cliniques et thérapeutiques du priapisme au CHU Gabriel Touré: étude de 36 cas. Pan Afr Med J [Internet]. 2014 [cité 9 oct 2023];17. Disponible sur: http://www.panafricanmed-journal.com/content/article/17/286/full/
18. Burnett AL. Pathophysiology of Priapism: Dysregulatory Erection Physiology Thesis. J Urol. juill 2003;170(1):26-34.
19. Pryor J, Akkus E, Alter G, Jordan G, Lebret T, Levine L, et al. Priapism. J Sex Med. 1 juill 2004;1(1):116-20.
20. Patel PM, Slovacek H, Pahouja G, Patel HD, Cao D, Emerson J, et al. Socioeconomic Disparities and Risk Factors in Patients Presenting With Ischemic Priapism: A Multi-Institutional Study. Urology. mai 2022;163:50-5.
21. Sidhu AS, Wayne GF, Kim BJ, Anderson AGS, Cordon BH, Caso JR, et al. The Hemodynamic Effects of Intracavernosal Phenylephrine for the Treatment of Ischemic Priapism. J Sex Med. 1 juill 2018 ;15(7):990-6.
Metrics
Downloads
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 M Halidou, A Georges Thomas, A Kodo, O Habou, H Adamou